News
OPTN
9.60
0.00%
0.00
*News On Optinose Inc. (OPTN) Now Under PRTK.XX
Dow Jones · 05/21/2025 21:08
Optinose Acquired by Paratek Pharmaceuticals for $330 Million
TipRanks · 05/21/2025 12:57
Paratek Pharmaceuticals completes acquisition of Optinose
TipRanks · 05/21/2025 12:30
PARATEK PHARMACEUTICALS COMPLETES ACQUISITION OF OPTINOSE, CREATING AN EXPANDED PORTFOLIO OF SPECIALTY THERAPIES
Reuters · 05/21/2025 12:26
HC Wainwright & Co. Reiterates Neutral on OptiNose, Maintains $9 Price Target
Benzinga · 05/19/2025 10:39
Hold Rating for Optinose Amid Acquisition Uncertainty and Financial Concerns
TipRanks · 05/19/2025 10:27
Weekly Report: what happened at OPTN last week (0512-0516)?
Weekly Report · 05/19/2025 09:12
Optinose Stockholders Approve Merger with Paratek
TipRanks · 05/16/2025 16:57
Analysts Offer Insights on Healthcare Companies: Celcuity (CELC), InfuSystem Holdings (INFU) and Optinose (OPTN)
TipRanks · 05/15/2025 13:00
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 05/15/2025 00:25
OptiNose: Q1 Earnings Snapshot
Barchart · 05/14/2025 18:18
Weekly Report: what happened at OPTN last week (0505-0509)?
Weekly Report · 05/12/2025 09:12
Weekly Report: what happened at OPTN last week (0428-0502)?
Weekly Report · 05/05/2025 09:12
Weekly Report: what happened at OPTN last week (0421-0425)?
Weekly Report · 04/28/2025 09:13
Weekly Report: what happened at OPTN last week (0414-0418)?
Weekly Report · 04/21/2025 09:13
Weekly Report: what happened at OPTN last week (0407-0411)?
Weekly Report · 04/14/2025 09:12
Goldman Sachs, J&J, To Report Earnings As Investors Watch Out For Retail Sales Data
Seeking Alpha · 04/12/2025 15:00
Catalyst Watch: Meta takes on the FTC, Taiwan Semi earnings, and Amazon satellites take flight
Seeking Alpha · 04/11/2025 19:00
Weekly Report: what happened at OPTN last week (0331-0404)?
Weekly Report · 04/07/2025 09:12
Weekly Report: what happened at OPTN last week (0324-0328)?
Weekly Report · 03/31/2025 09:13
More
Webull provides a variety of real-time OPTN stock news. You can receive the latest news about Optinose through multiple platforms. This information may help you make smarter investment decisions.
About OPTN
OptiNose, Inc. is a specialty pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. It has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.